纖維肌痛治療市場規模、佔有率和成長分析（按藥物類別、診斷方法、給藥途徑、藥物類型、治療途徑、通路和地區分類）—2026-2033年產業預測

預計到 2024 年，全球纖維肌痛治療市場規模將達到 37.9 億美元，到 2025 年將成長至 41 億美元，到 2033 年將成長至 77 億美元，在預測期（2026-2033 年）內複合年成長率為 8.2%。

全球纖維肌痛治療市場約佔受這種慢性疼痛疾病影響的成年人口的2%，其中女性患者居多，反映出對有效症狀管理的巨大需求。鑑於目前尚無治療方法，醫療服務提供者正致力於開發多種治療方案，旨在改善患者的生活品質。這些方案包括藥物治療、生活方式調整以及非藥物療法，這些療法旨在緩解全身疼痛、改善睡眠和改善認知障礙。纖維肌痛症狀的複雜性決定了需要採取多管齊下的治療方法，制定個人化的治療方案，以滿足每位患者的獨特需求和反應。隨著人們對纖維肌痛的認知不斷提高，該市場有望擴大創新治療方法，以應對纖維肌痛患者面臨的多重挑戰。

推動全球纖維肌痛治療市場發展的因素

全球纖維肌痛治療市場的主要促進因素之一是醫護人員和患者對纖維肌痛的認知度和診斷率不斷提高。隨著人們對這種以全身疼痛和疲勞為特徵的疾病的了解不斷加深，越來越多的人因症狀尋求醫療幫助，從而提高了診斷率。這種日益成長的認知度正在推動標靶治療和治療方法的研發，進而促進市場成長。此外，患者權益倡導組織的興起和醫療服務可近性的改善，也幫助患者更了解各種治療方案，進一步推動了對有效纖維肌痛治療的需求。

限制全球纖維肌痛治療市場的因素

全球纖維肌痛治療市場面臨的主要限制因素之一是醫護人員和患者對纖維肌痛的認知和了解不足。由於症狀複雜且與其他疾病症狀重疊，這種慢性疾病常被誤診或漏診，導致治療選擇不足，患者滿意度下降。專業資源和實證治療通訊協定的匱乏會阻礙有效治療，使患者感到缺乏支持。此外，醫療保健系統和保險覆蓋範圍的差異也會限制患者獲得所需治療，進一步加劇纖維肌痛患者的治療困境。

全球纖維肌痛治療市場趨勢

全球纖維肌痛治療市場正呈現顯著的發展趨勢，主要企業紛紛推出創新治療方法以鞏固其市場地位。各公司致力於研發和核准針對纖維肌痛的下一代治療方法，展現了其應對患者面臨的獨特挑戰的堅定承諾。這種充滿活力的市場環境體現在現有藥物的策略性擴張，反映了各企業為豐富治療選擇所做的不懈努力。隨著研究的不斷深入和新治療方法的湧現，市場成長預期依然很高，這凸顯了纖維肌痛管理領域的不斷演變以及對有效解決方案日益成長的需求。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 案例研究
• 監管環境

全球纖維肌痛治療市場規模（按藥物類別和複合年成長率分類）（2026-2033 年）

• 抗憂鬱症
• 抗癲癇藥物
• 肌肉鬆弛劑
• 其他

全球纖維肌痛治療市場規模（按診斷方法和複合年成長率分類）（2026-2033 年）

• 血液檢查
• 身體檢查

全球纖維肌痛治療市場規模（按給藥途徑和複合年成長率分類）（2026-2033 年）

• 口服
• 注射
• 外用藥物

全球纖維肌痛治療市場規模（按藥物類型和複合年成長率分類）（2026-2033 年）

• 品牌產品
• 學名藥

全球纖維肌痛治療市場規模（依治療管道分類）及複合年成長率（2026-2033 年）

• 醫院
• 診所
• 居家照護

全球纖維肌痛治療市場規模（依通路分類）及複合年成長率（2026-2033 年）

• 醫院藥房
• 零售藥房
• 網路藥房

全球纖維肌痛治療市場規模（按最終用戶分類）及複合年成長率（2026-2033 年）

• 成人
• 兒童

全球纖維肌痛治療市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

主要企業簡介

• Pfizer Inc.（USA）
• AbbVie Inc.（USA）
• Eli Lilly and Company（USA）
• F. Hoffmann-La Roche Ltd.（Switzerland）
• GlaxoSmithKline plc（UK）
• Aptinyx Inc.（USA）
• Tonix Pharmaceuticals Holding Corp.（USA）
• Virios Therapeutics（USA）
• Astellas Pharma Inc.（Japan）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Boehringer Ingelheim GmbH（Germany）
• Novartis AG（Switzerland）
• Johnson & Johnson（USA）
• Merck & Co., Inc.（USA）
• Bristol-Myers Squibb Company（USA）
• Takeda Pharmaceutical Company Limited（Japan）
• Sun Pharmaceutical Industries Ltd.（India）
• Mylan NV（USA）
• Lupin Limited（India）

結論與建議

Global Fibromyalgia Treatment Market size was valued at USD 3.79 Billion in 2024 and is poised to grow from USD 4.1 Billion in 2025 to USD 7.7 Billion by 2033, growing at a CAGR of 8.2% during the forecast period (2026-2033).

The global market for fibromyalgia treatment reflects a significant demand for effective symptom management, catering to the approximately 2% of adults affected by this chronic pain disorder, particularly among women. Recognizing the absence of a cure, healthcare providers focus on a variety of treatment options that aim to improve patients' quality of life. These include medications, lifestyle changes, and non-pharmacological therapies specifically designed to relieve widespread pain, enhance sleep, and tackle cognitive difficulties. The complexity of fibromyalgia's diverse symptoms necessitates a multidisciplinary approach, promoting personalized treatment plans that adapt to each individual's unique needs and responses. As awareness grows, there is potential for expanding innovative therapies in this market, addressing the multifaceted challenges faced by those living with fibromyalgia.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Fibromyalgia Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Fibromyalgia Treatment Market Segments Analysis

Global Fibromyalgia Treatment Market is segmented by Drug Class, Diagnosis Method, Route of Administration, Drug Type, Treatment Channel, Distribution Channel, End User and region. Based on Drug Class, the market is segmented into Antidepressants, Antiepileptics, Muscle Relaxants and Others. Based on Diagnosis Method, the market is segmented into Blood Tests and Physical Examination. Based on Route of Administration, the market is segmented into Oral, Injectable and Topical. Based on Drug Type, the market is segmented into Branded and Generic. Based on Treatment Channel, the market is segmented into Hospitals, Clinics and Homecare. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on End User, the market is segmented into Adults and Pediatrics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Fibromyalgia Treatment Market

One of the key market drivers for the global fibromyalgia treatment market is the increasing awareness and diagnosis of fibromyalgia among healthcare professionals and patients. As knowledge regarding fibromyalgia-a condition characterized by widespread pain and fatigue-grows, more individuals are seeking medical attention for their symptoms, leading to higher diagnosis rates. This heightened awareness promotes the development of targeted therapies and treatment modalities, propelling market growth. Additionally, the rise in patient advocacy groups and improved access to healthcare services foster an environment where individuals are more informed about their options, further driving the demand for effective fibromyalgia treatments.

Restraints in the Global Fibromyalgia Treatment Market

One significant market restraint in the global fibromyalgia treatment market is the lack of awareness and understanding of fibromyalgia among both healthcare professionals and patients. This chronic condition is often misdiagnosed or underdiagnosed due to its complex symptoms and overlap with other disorders, leading to inadequate treatment options and patient dissatisfaction. The limited availability of specialized resources and evidence-based treatment protocols can hinder effective management and result in patients feeling unsupported. Furthermore, variations in healthcare systems and insurance coverage can restrict access to necessary therapies, further complicating the treatment landscape for fibromyalgia sufferers.

Market Trends of the Global Fibromyalgia Treatment Market

The Global Fibromyalgia Treatment market is witnessing significant trends driven by the introduction of innovative therapies by key players seeking to enhance their presence. Companies are focusing on the development and approval of next-generation treatments tailored specifically for fibromyalgia, indicating a robust commitment to addressing the unique challenges faced by patients. This dynamic environment is characterized by the strategic expansion of indications for existing medications, reflecting a concerted effort to diversify treatment options. As research progresses and new therapies emerge, expectations for market growth remain high, underscoring the evolving landscape of fibromyalgia management and the increasing need for effective solutions.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Landscape

Global Fibromyalgia Treatment Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• Antidepressants
• Antiepileptics
• Muscle Relaxants
• Others

Global Fibromyalgia Treatment Market Size by Diagnosis Method & CAGR (2026-2033)

• Market Overview
• Blood Tests
• Physical Examination

Global Fibromyalgia Treatment Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Injectable
• Topical

Global Fibromyalgia Treatment Market Size by Drug Type & CAGR (2026-2033)

• Market Overview
• Branded
• Generic

Global Fibromyalgia Treatment Market Size by Treatment Channel & CAGR (2026-2033)

• Market Overview
• Hospitals
• Clinics
• Homecare

Global Fibromyalgia Treatment Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Fibromyalgia Treatment Market Size by End User & CAGR (2026-2033)

• Market Overview
• Adults
• Pediatrics

Global Fibromyalgia Treatment Market Size & CAGR (2026-2033)

• North America (Drug Class, Diagnosis Method, Route of Administration, Drug Type, Treatment Channel, Distribution Channel, End User)
  • US
  • Canada
• Europe (Drug Class, Diagnosis Method, Route of Administration, Drug Type, Treatment Channel, Distribution Channel, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Diagnosis Method, Route of Administration, Drug Type, Treatment Channel, Distribution Channel, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Diagnosis Method, Route of Administration, Drug Type, Treatment Channel, Distribution Channel, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Diagnosis Method, Route of Administration, Drug Type, Treatment Channel, Distribution Channel, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aptinyx Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tonix Pharmaceuticals Holding Corp. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Virios Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations